Nexien BioPharma, Inc.

OTC: NXEN · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Glendale, CO · BoulderCIK 0001625288Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ 19GM —SS 28

v0.1 · 25/100 weight · pillars only

↑ listing tenure, workforce scale · ↓ return on assets, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$239.1k

Employees

as of 2026-08-30

Market cap

$7.1k

as of 2026-08-30

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02017

Net income-$239.1k-$239.1k2024

Operating income$11.5M$11.5M2024

Total assets$4.2k$4.2k2024

Liabilities$365.4k$365.4k2024

Equity-$361.2k-$361.2k2024

Revenue trend

FY2015 – FY2017 · USD

FY15

FY16

FY17

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Nexien BioPharma, Inc.’s revenue?

Nexien BioPharma, Inc. booked $0 in FY2017 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Ceres Ventures, Inc.——HTC Purenergy Inc.——SES Solar Inc.——FluoroPharma Medical, Inc.——PAO Group, Inc.——NovAccess Global Inc.——

Neighbors

Boulder →

Edgewise Therapeutics, Inc.——Enliven Therapeutics, Inc.——Infleqtion Inc——Solid Power, Inc.$17.9M38D Gores Holdings XI, Inc.——Gloo Holdings, Inc.$94.7M31D

Key facts

CEORichard S. Greenberg

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersGlendale, CO

ExchangeOTC: NXEN

Employees10

IPO date2017-11-29

Latest filings

10-Q2025-05-14 10-Q2025-02-14 10-Q2024-11-18 10-K2024-10-22 10-Q2024-05-15 10-Q2024-02-20 10-Q2023-11-14 10-K2023-09-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.